MetaCap

AnaptysBio Inc. (ANAB)

NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD

46.63-0.77 (-1.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANAB stock chart

Technical analysis

Key statistics

All statistics
52-week range
26.01 – 72.36
Day range
46.05 – 47.66
Volume / Avg
432.44K / 496.92K
Beta
—

52-week range

$26.01$72.36

ANAB stock today

On Nov 20, ANAB ended the session at $46.63, shedding $0.77 (1.62%), versus the S&P 500's 3.70% decline. At this level, ANAB sits in the middle of its 52-week range of $26.01 to $72.36: 35.6% below the high, set on May 5, 2026 and 79.3% above the low. ANAB is up 44.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 76.6%.

At 7.2x trailing earnings, AnaptysBio trades below the peer-group median of 9.4x. Its forward P/E of 8.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About AnaptysBio

Company profile

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel R. Faga
Headquarters
San Diego, CA
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, AnaptysBio generated $234.6 million in revenue, up 157.0% from fiscal 2024, its 3rd consecutive year of revenue growth. AnaptysBio reported a net loss of $13.2 million, compared with a loss of $145.2 million a year earlier. Operating margin was 96.7%.

AnaptysBio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$234.60M$91.28M$17.16M$10.29M$63.17M
Growth+157.01%+432.03%+66.78%-83.72%-15.77%
Net income$-13.23M$-145.23M$-163.62M$-128.72M$-57.80M
EPS (diluted)$-0.44$-4.92$-6.08$-4.57$-2.11

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$87.25+87.11%

  • Strong buy 3
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $60.00High $140.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.11 vs $0.41
Surprise
-73.17%

ANAB news

All ANAB news

AnaptysBio peers

Health Care sector
ANAB peer companies
CompanyPrice% ChgMarket capCompare
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs ANAB
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs ANAB
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs ANAB
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs ANAB
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs ANAB
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs ANAB
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs ANAB
QUREuniQure N.V.19.35-4.35%$1.36Bvs ANAB

Indexes, lists and sector

AnaptysBio stock FAQ

What is AnaptysBio's stock price today?

ANAB last traded at $46.63 as of Nov 20, 4:00 PM EST, down 1.62% on the day. Prices are delayed at least 15 minutes.

Does AnaptysBio pay a dividend?

No. AnaptysBio does not currently pay a regular cash dividend.

What is ANAB's P/E ratio?

ANAB trades at a trailing P/E ratio of 7.15 and a forward P/E of 8.66, compared with a median of 9.4 for its closest peers.

Who is AnaptysBio's CEO?

Mr. Daniel R. Faga is the chief executive officer of AnaptysBio Inc..

Has ANAB ever split its stock?

Yes. The most recent ANAB stock split was a 15-for-10 split on Apr 20, 2026.

What is the ANAB 52-week high?

The 52-week high for ANAB is $72.36 and the 52-week low is $26.01. The stock is currently 35.6% below its high.

Compare ANAB